Phenotypic and Genomic Characterization of AmpC-Producing Klebsiella pneumoniae From Korea
2018; 38(4): 367-370
Ann Lab Med 2018; 38(4): 324-330
Published online March 30, 2018 https://doi.org/10.3343/alm.2018.38.4.324
Copyright © Korean Society for Laboratory Medicine.
John Hoon Rim, M.D.1,2,3, Hyunsoo Kim, M.D.4, Hyukmin Lee, M.D.1*, Dongeun Yong, M.D.1, Seok Hoon Jeong, M.D.1, and Kyungwon Lee, M.D.1
1Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea.
2Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
3Department of Medicine, Physician-Scientist Program, Yonsei University Graduate School of Medicine, Seoul, Korea.
4Department of Laboratory Medicine, The National Police Hospital, Seoul, Korea.
Correspondence to: Corresponding author: Hyukmin Lee. Department of Laboratory Medicine, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, Korea. Tel: +82-2-2019-3777, Fax: +82-2-2057-8926, hmlee.labmed@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
We investigated the molecular epidemiological characteristics and antimicrobial susceptibility pattern of penicillinase-producing
We collected 804 PPNG isolates from diverse hospitals and clinics mainly located in Seoul, Korea, over a period of 11 years (2005?2015). Isolate susceptibility to seven antimicrobials was determined using the agar dilution test. The molecular epidemiological characteristics of the isolates were determined by Sanger sequencing of
Among 72 fully sequenced PPNG isolates, sixteen (22.2%) possessed TEM-135. All TEM-135 isolates had a common silent mutation (c.18C>T), which was previously unreported. We observed a pattern of continuous increase in the number of TEM-135 isolates since 2012. The median and 90% minimum inhibitory concentration of azithromycin were substantially lower in the TEM-135 group than in the non-PPNG and TEM-1 groups. All TEM-135 isolates showed different NG-MAST types and predominantly harbored Toronto/Rio (75%) plasmids. A comprehensive comparative analysis of PPNG with TEM-135 according to NG-MAST, plasmid type, and year of isolation revealed a wide distribution.
The proportion of TEM-135 PPNG has continuously increased since 2012, in association with clonal spread. The difference at position 18 of the TEM-135 sequence can be interpreted as the existence of multiple clonal complexes. The possibility that TEM-135 was acquired via foreign plasmids requires careful follow-up and continuous monitoring of TEM-135 to ascertain whether it constitutes a step towards evolutionary change.
Keywords: Penicillinase-producing
Penicillin treatment failure was first reported soon after the introduction of penicillin administration in the 1940s; dissemination of penicillin resistance has made this antibiotic useless since the 1950s [1]. The mechanism of penicillin resistance prevalent during the 1960s and mid-1970s is associated with mutations in chromosomal genes (mainly
TEM-135, which has a single amino acid change (M182T) compared with the TEM-1 sequence, was first reported in 2005 [6], and its frequency and genetic diversity have been consistently evaluated in many countries. The clinical significance of TEM-135 remains unclear, as there are no major differences in the minimal inhibitory concentrations (MICs) of penicillin and extended-spectrum cephalosporins; however, the emergence of TEM-135 could signify the introduction of other TEM β-lactamases with an extended β-lactam hydrolytic spectrum through mutation or plasmid acquisition under the high selective pressure of cephalosporin usage. We aimed to determine the prevalence of TEM-135 and compare the characteristics of TEM-1- and TEM-135-producing
A total of 804 isolates were collected over 11 years (2005–2015) from 40 diverse hospitals and primary-care clinics in Korea to test for the presence of the TEM-135 gene. This study was approved by the Institutional Review Board of the Human Research Protection Center in the Yonsei University Health System (4-2016-0359). Transgrow medium was used as the transport medium to minimize the loss of viable
The antimicrobial susceptibility of all isolates to the antibiotics (penicillin G, tetracycline, ceftriaxone, spectinomycin, ciprofloxacin, nalidixic acid, and azithromycin) was determined using the CLSI disk diffusion method [7]. MIC was calculated using the agar dilution test according to the CLSI guidelines [8] for all antibiotics except azithromycin, for which the European Committee on Antimicrobial Susceptibility Testing (EUCAST) cut-off values were used [9]. The median and 90% MIC values (MIC50 and MIC90) and range were evaluated for the three groups of isolates: non-PPNG, PPNG with TEM-1, and PPNG with TEM-135.
DNA was extracted from PPNG bacterial suspensions, using the QIAquick gel extraction kit (Qiagen, Hilden, Germany). Mismatch amplification mutation assay (MAMA) PCR was performed to detect the
To evaluate the molecular epidemiology of the TEM-135 isolates, NG-MAST was performed by sequencing the
PPNG isolates accounted for 11.6% (N=93) of the 804 isolates, with patterns fluctuating by collection year (Fig. 1). Only 72 PPNG isolates (77.4%) were available for further molecular investigation because of loss or deterioration of the isolates during the storage period. These 72 isolates were subjected to full sequence analysis to determine the presence of TEM-1 or TEM-135; 22.2% (N=16) were shown to harbor TEM-135. The first TEM-135 isolate was identified in 2006, and the number of TEM-135 isolates has continuously increased since 2012. Although no variant types other than TEM-1 and TEM-135 were found, all isolates possessed a silent mutation, c.18C>T, which does not change the original amino acid (Proline) compared with the previously reported
Of the 72 PPNG isolates, 52 (38 TEM-1 and 14 TEM-135 isolates) were randomly selected (mainly because of strain availability) for antimicrobial susceptibility testing with seven antibiotics. The proportions of susceptible isolates for the seven antibiotics were similar between the TEM-1 group and TEM-135 group, whereas the non-PPNG group showed a different pattern (Table 2). Comparison of the MIC50 and MIC90 (determined using the agar dilution test) of the three groups (non-PPNG, PPNG with TEM-1, and PPNG with TEM-135) showed that the MIC50 and MIC90 of ceftriaxone and cefixime were significantly lower in the TEM-135 than in the other groups (all values ≤0.008 µg/mL). Additionally, the MIC50 and MIC90 of azithromycin in the TEM-135 group were also lower than those in the TEM-1 group (MIC50=0.06 µg/mL and MIC90=0.25 µg/mL for the TEM-135 group). No significant changes in antimicrobial resistance trends were observed in the TEM-1, TEM-135, and non-PPNG groups (
The STs of 72 PPNG isolates were determined by NG-MAST in order to elucidate the molecular epidemiology of plasmids possessing certain types of penicillinases; 59 different STs were identified, indicating heterogeneous epidemiological distribution (Fig. 2). The STs bearing TEM-135 were dispersed throughout the genetic tree (generated based on
The emergence of PPNG was one reason for the use of extended-spectrum cephalosporins, including ceftriaxone and cefixime; the appearance of TEM-135 could constitute another turning point in gonococcal treatment through the evolution or introduction of novel β-lactamases to
The antimicrobial susceptibility patterns of ceftriaxone, cefixime, azithromycin, and tetracycline in PPNG with TEM-135 differed from those in PPNG with TEM-1. Although all PPNG isolates were susceptible to ceftriaxone and cefixime, the MIC50 and MIC90 of both antibiotics were much lower in PPNG with TEM-135 (both values ≤0.008 µg/mL) than in PPNG with TEM-1 (0.03 µg/mL and 0.12 µg/mL, respectively). The rate of azithromycin-susceptible isolates was 100% in TEM-135 strains, but 60% in TEM-1 strains. The MIC50 of tetracycline in TEM-135 and TEM-1 PPNG was 0.5 µg/mL and 4 µg/mL, respectively, and the rates of resistance were 30.8% and 78.1%, respectively. Although a previous study conducted in England utilizing a similar approach discovered statistically higher ciprofloxacin and tetracycline MIC values in TEM-135 strains [14], our results do not support such trends. However, they may suggest clonal relatedness consisting of isolates highly susceptible to ceftriaxone and cefixime that can be discriminated from TEM-1 PPNG, despite the high selective pressure of ceftriaxone usage in Korea.
This hypothesis can be partially supported by our phylogenetic and plasmid analyses. The phylogenetic tree based on partial
The predominance of the Toronto/Rio plasmid type in TEM-135 PPNG revealed in our study is in line with previous epidemiological studies conducted in other countries [10,15,16,19], although only one study from England reported the predominance of the Asian plasmid type [14]. Therefore, we assume that a specific plasmid (Toronto/Rio) has been distributed worldwide. The ceftriaxone and cefixime MIC values of isolates with an Asian plasmid type (0.06 µg/mL, respectively) were higher than the values of isolates with other plasmid types; however, the number of isolates was too small to draw any definitive conclusions.
A recent report identified four novel TEM alleles from globally collected strains [19]; we did not identify any new TEM alleles other than TEM-1 and TEM-135. Interestingly, all isolates in this study had a thymidine instead of cytosine at nucleic acid position 18 compared with the previously reported
In conclusion, the proportion of TEM-135 PPNG has continuously increased during the past four years and most of the isolates are highly susceptible to ceftriaxone and cefixime despite the high selective pressure of ceftriaxone usage in Korea. The recent increase in TEM-135 PPNG proportion is associated with clonal spread; however, we hypothesize that most of the isolates have originated from relatively low ceftriaxone selective pressure environments. Moreover, the difference at position 18 of the TEM-135 sequence can be interpreted as the presence of at least two clonal complexes, one of which is thought to be associated with the Japanese sequence, even though direct connection cannot be proved. The possibility of foreign import requires rigorous follow-up to control the foreign acquisition of novel resistance and continuous monitoring of TEM-135 to elucidate whether TEM-135 constitutes a step towards evolutionary change of resistance to prevent the dissemination.
There are no conflicts of interest to declare.
We are very grateful to Minhee Sohn and Hayeon Kim for collecting the isolates.
Chronological changes in the percentage of isolates with TEM-1 or TEM-135 β-lactamase among all the
Genetic distance tree and plasmid types of penicillinase-producing
Abbreviation: NG-MAST,
Alterations in the nucleic acid and amino acid sequences of TEM-1 and TEM-135 β-lactamase
Species (GenBank accession number) | Position of nucleic acid alteration (amino acid alteration) | |||
---|---|---|---|---|
18 (Silent) Wild type: T, Mutant: C | 539 (Met182Thr) Wild type: T, Mutant: C | 547 (Ala185Thr) Wild type: G, Mutant: A | ||
TEM-1 | T | T | G | |
TEM-135 | T | G | ||
TEM-135 | G | |||
TEM-135 | T | G | ||
TEM-220 | T | |||
TEM-135 | T | G |
Comparison of resistance proportion and antibiotic geometric mean MIC values according to the presence of TEM-1 or TEM-135
Antibiotics | MIC (µg/mL) | Antimicrobial susceptibility (%) | |||||
---|---|---|---|---|---|---|---|
Range | MIC50 | MIC90 | Susceptible | Intermediate | Resistant | ||
TEM-1 PPNG (N = 38)* | |||||||
Penicillin | 2–256 | 64 | 128 | 0 | 0 | 100 | |
Ceftriaxone | ≤ 0.008–0.12 | 0.03 | 0.12 | 100 | 0 | ||
Cefixime | ≤ 0.008–0.25 | 0.03 | 0.12 | 100 | 0 | ||
Spectinomycin | 16–32 | 32 | 32 | 100 | 0 | 0 | |
Tetracycline | 0.25–128 | 4 | 32 | 9.4 | 12.5 | 78.1 | |
Ciprofloxacin | 0.06–32 | 2 | 16 | 3.1 | 6.3 | 90.6 | |
Azithromycin† | ≤ 0.06–8 | 0.25 | 1 | 60.0 | 24.0 | 16.0 | |
TEM-135 PPNG (N = 14)‡ | |||||||
Penicillin | 32–256 | 128 | 128 | 0 | 0 | 100 | |
Ceftriaxone | ≤ 0.008–0.06 | ≤ 0.008 | ≤ 0.008 | 100 | 0 | ||
Cefixime | ≤ 0.008–0.06 | ≤ 0.008 | ≤ 0.008 | 100 | 0 | ||
Spectinomycin | 8–32 | 32 | 32 | 100 | 0 | 0 | |
Tetracycline | 0.25–32 | 0.5 | 32 | 15.4 | 53.8 | 30.8 | |
Ciprofloxacin | ≤ 0.008–8 | 2 | 4 | 15.4 | 0 | 84.6 | |
Azithromycin† | ≤ 0.06–0.25 | 0.06 | 0.25 | 100 | 0 | 0 | |
Non-PPNG (N = 529) | |||||||
Penicillin | ≤ 0.06–32 | 1 | 4 | 0 | 61.5 | 38.5 | |
Ceftriaxone | ≤ 0.008–0.25 | 0.03 | 0.12 | 100 | 0 | ||
Cefixime | ≤ 0.008–0.5 | 0.03 | 0.25 | 96.6 | 3.4 | ||
Spectinomycin | ≤ 4–32 | 32 | 32 | 100 | 0 | 0 | |
Tetracycline | ≤ 0.12–128 | 2 | 32 | 3.0 | 31.0 | 66.0 | |
Ciprofloxacin | ≤ 0.008–64 | 8 | 16 | 12.3 | 3.7 | 84.0 | |
Azithromycin† | ≤ 0.06–4 | 0.25 | 0.5 | 57.2 | 35.2 | 7.6 |